Developmental research of tailored immune-modulation therapy against refractory chronic hepatitis C.

据报道，大约50%的HCV基因型1和高滴度的慢性丙型肝炎患者通过48周的peg- ifn - α和利巴韦林治疗成功治疗。在本研究项目中，我们旨在阐明免疫反应如何参与HCV根除，并阐明免疫细胞动力学是否可以作为治疗反应的预测因子。在单因素分析中，SVR组治疗结束时预处理MDC频率和DC函数显著高于非SVR组。基于病毒、宿主因素和药物依从性的多变量分析显示，血小板计数和PDC频率是SVR的独立影响因素。因此，“免疫应答引导疗法”建立针对慢性丙型肝炎患者的个体化治疗方案是合理的。

It is reported that approximately 50% of chronic hepatitis C patients with HCV genotype 1 and high titer are successfully treated with 48-week peg-IFN-alfa and ribavirin therapy. In this research project, we aimed to clarify how immune responses are involved in HCV eradication, and elucidate if dynamics of immune cells could serve as predictor of therapeutic response in the treatment. In monovariate analyses, pretreatment MDC frequency and DC function at the end of treatment were significantly higher in the SVR group than those in the non-SVR one. Multivariate analyses based on viral and host factors and drug adherence revealed that platelet counts and PDC frequency were independently contributed to the SVR. Therefore, "immune response-guided therapy" is rational in the establishment of a tailored treatment for chronic hepatitis C patients.